Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIK THERAPEUTICS INC. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action represents the entirety of the company's active prosecution for its therapeutic innovations. In the Biotechnology & Pharmaceuticals sector, maintaining 1 pending office action requires careful management of USPTO deadlines to ensure that the intellectual property protection remains on track with clinical trials.
The prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This focus within 1 distinct art unit suggests that the technical scope of the application is highly specialized and does not cross into other technical disciplines. Because there is only 1 distinct examiner involved, the company's strategy is entirely dependent on the interpretation of a single individual at the patent office.
KATAKAM, SUDHAKAR is the busiest examiner for the portfolio, currently managing 1 pending office action. Since this 1 pending office action is the only one currently active, the interactions with KATAKAM, SUDHAKAR will determine the immediate success of the company's patent efforts. Practitioners should review the specific tendencies of KATAKAM, SUDHAKAR to navigate the 1 pending office action effectively.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928879 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | KATAKAM, SUDHAKAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17928879 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | KATAKAM, SUDHAKAR | 1658 | §112 | Final Rejection | — | Pending | Nov 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIK THERAPEUTICS INC. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sudhakar Katakam has the most, with 1 of BIK THERAPEUTICS INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
